Imatinib (STI571), a selective inhibitor targeting Abl as well as c-Kit and the platelet-derived growth factor receptor, has been tested for the efficacy and toxicities in metastatic melanoma patients, suggesting that c-Kit might be a drugging target for treatment of melanoma [8]. This evidence concerns the gene KIT and metastatic melanoma.